Key Takeaways
- • Sir Andrew Witty, former Chief Executive Officer of GlaxoSmithKline, joined Hatteras Venture Partners as a part-time venture partner in September 2026, signaling the firm's expansion into life sciences and healthcare investment expertise.
- • Ned Sharpless, M.D., was appointed Managing Director of Hatteras Discovery Innovation, a specialized division focused on discovery-stage investments within the firm's broader venture strategy.
- • The appointments represent Hatteras Venture Partners' strategic expansion of its proven investment approach through the recruitment of senior executives with deep sector expertise and institutional credibility.
- • Witty's addition to the leadership team brings pharmaceutical industry experience and executive-level networks critical for healthcare-focused venture investments.
Summary
Hatteras Venture Partners announced two significant leadership appointments in September 2026 designed to strengthen its investment capabilities and expand its strategic reach. Sir Andrew Witty, the former Chief Executive Officer of GlaxoSmithKline, joined the firm as a part-time venture partner, adding substantial pharmaceutical and life sciences expertise to the investment team. Simultaneously, Ned Sharpless, M.D., was named Managing Director of Hatteras Discovery Innovation, a newly formalized division within the firm dedicated to discovery-stage investments.
The dual appointments underscore Hatteras Venture Partners' commitment to deepening its presence in the healthcare and life sciences sectors, areas where both executives bring exceptional credentials. Witty's tenure as CEO of one of the world's largest pharmaceutical companies positions him to identify high-potential early-stage companies and evaluate scientific and commercial viability within the sector. Sharpless's medical background and leadership of the discovery innovation division further solidify the firm's focus on translating scientific advances into viable commercial ventures.
These leadership moves reflect a broader institutional strategy to expand proven investment methodologies by recruiting sector-specific expertise at the senior level. By attracting executives of Witty's and Sharpless's caliber, Hatteras Venture Partners signals confidence in its investment thesis while providing limited partners with access to deep industry networks and operational experience. The appointments are consistent with how leading venture firms scale their capabilities in target sectors through strategic talent acquisition rather than organic team building alone.
The dual appointments underscore Hatteras Venture Partners' commitment to deepening its presence in the healthcare and life sciences sectors, areas where both executives bring exceptional credentials. Witty's tenure as CEO of one of the world's largest pharmaceutical companies positions him to identify high-potential early-stage companies and evaluate scientific and commercial viability within the sector. Sharpless's medical background and leadership of the discovery innovation division further solidify the firm's focus on translating scientific advances into viable commercial ventures.
These leadership moves reflect a broader institutional strategy to expand proven investment methodologies by recruiting sector-specific expertise at the senior level. By attracting executives of Witty's and Sharpless's caliber, Hatteras Venture Partners signals confidence in its investment thesis while providing limited partners with access to deep industry networks and operational experience. The appointments are consistent with how leading venture firms scale their capabilities in target sectors through strategic talent acquisition rather than organic team building alone.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.